1. APIs
  2. Norethindrone
  3. Metabolites
  4. 3β,5α-Tetrahydronorethindrone

3β,5α-Tetrahydronorethindrone

Structure

Progestogen Receptor Activity

Significantly reduced progestational activity

library_books

References

  1. Lemus, A. E.; Zaga, V.; Santillan, R.; Garcia, G. A.; Grillasca, I.; Damian-Matsumura, P.; Jackson, K. J.; Cooney, A. J.; Larrea, F.; Perez-Palacios, G., The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. Journal of Endocrinology 2000, 165 (3), 693-702.
    2. (View all citations for this reference)
  2. Larrea, F.; Garcia-Becerra, R.; Lemus, A. E.; Garcia, G. A.; Perez-Palacios, G.; Jackson, K. J.; Coleman, K. M.; Dace, R.; Smith, C. L.; Cooney, A. J., A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha. Endocrinology 2001, 142 (9), 3791-3799.
    3. (View all citations for this reference)

Androgen Receptor Activity

"The 5α-reduction of NET, even if confers a relatively high binding affinity to the AR, diminishes its androgenic potency."

library_books

References

  1. Stanczyk FZ. All progestins are not created equal. Steroids. 2003; 68:879-90.
    2. (View all citations for this reference)

Estrogen Receptor Activity

selectively activates ERα. "Able to activate gene transcription via ER, although its binding affinity is lower than estradiol."

library_books

References

  1. Stanczyk FZ. All progestins are not created equal. Steroids. 2003; 68:879-90.
    2. (View all citations for this reference)
  2. Lemus, A. E.; Zaga, V.; Santillan, R.; Garcia, G. A.; Grillasca, I.; Damian-Matsumura, P.; Jackson, K. J.; Cooney, A. J.; Larrea, F.; Perez-Palacios, G., The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. Journal of Endocrinology 2000, 165 (3), 693-702.
    3. (View all citations for this reference)
  3. Larrea, F.; Garcia-Becerra, R.; Lemus, A. E.; Garcia, G. A.; Perez-Palacios, G.; Jackson, K. J.; Coleman, K. M.; Dace, R.; Smith, C. L.; Cooney, A. J., A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha. Endocrinology 2001, 142 (9), 3791-3799.
    4. (View all citations for this reference)

References

  1. Walker, C. J.; Cowan, D. A.; James, V. H. T.; Lau, J. C. Y.; Kicman, A. T., Doping in sport: 3. Metabolic conversion of oral norethisterone to urinary 19-norandrosterone. Steroids 2009, 74 (3), 341-349.
    2. (View all citations for this reference)
  2. Besse, J. P.; Garric, J., Progestagens for human use, exposure and hazard assessment for the aquatic environment. Environ. Pollut. 2009, 157 (12), 3485-3494.
    3. (View all citations for this reference)
  3. Stanczyk FZ. All progestins are not created equal. Steroids. 2003; 68:879-90.
    4. (View all citations for this reference)
  4. ChEMBL: Norethisterone (View all citations for this reference)
  5. Pommier, F.; Sioufi, A.; Godbillon, J. Simultaneous Determination of Norethisterone and Six Metabolites in Human Plasma by Capillary Gas Chromatography with Mass-Selective Detection. J. Chromatogr. B Biomed. Sci. Appl. 1995, 674 (2), 155–165. (View all citations for this reference)